Literature DB >> 21855423

Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens.

Megan R Nelson1, Craig R Adamski, Audrey Tluczek.   

Abstract

BACKGROUND: Newborn screening (NBS) for cystic fibrosis (CF) has become standard practice in many countries. Consequently, the prevalence of infants with intermediate sweat test results has increased. This study examined clinical practices in the United States (US) related to intermediate sweat test results subsequent to NBS.
METHODS: Respondents from 77 (47% response rate) US CF centers completed telephone surveys documenting clinical practices related to intermediate sweat chloride levels (30-59 mmol/L) following abnormal NBS.
RESULTS: Thirty percent of centers followed CF Foundation guidelines for classifying intermediate results. There was much variability in sweat testing procedures, diagnostic labels, additional diagnostics, addressing prognosis, and services offered to parents. CF center staff identified a need for resources to better address the uncertainty associated with intermediate results.
CONCLUSION: Results suggest the need for education regarding current guidelines and consensus regarding the nomenclature and services offered to families of newborns with intermediate sweat test results.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21855423      PMCID: PMC3616645          DOI: 10.1016/j.jcf.2011.07.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  8 in total

1.  A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis.

Authors:  S J Mayell; A Munck; J V Craig; I Sermet; K G Brownlee; M J Schwarz; C Castellani; K W Southern
Journal:  J Cyst Fibros       Date:  2008-10-28       Impact factor: 5.482

2.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

3.  A welcome link for patients who are waiting.

Authors:  Joan Hamilton; Barb Grant
Journal:  Can Nurse       Date:  2006-03

4.  The power of hope: being a doctor is more than relying solely on the numbers.

Authors:  A N Godshalk; G C Brown; H C Brown; M M Brown
Journal:  Br J Ophthalmol       Date:  2008-06       Impact factor: 4.638

5.  Newborn screening in Latin America at the beginning of the 21st century.

Authors:  G J C Borrajo
Journal:  J Inherit Metab Dis       Date:  2007-08-14       Impact factor: 4.982

6.  When the cystic fibrosis label does not fit: a modified uncertainty theory.

Authors:  Audrey Tluczek; Anne Chevalier McKechnie; Patrice A Lynam
Journal:  Qual Health Res       Date:  2010-02

7.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

8.  European best practice guidelines for cystic fibrosis neonatal screening.

Authors:  Carlo Castellani; Kevin W Southern; Keith Brownlee; Jeannette Dankert Roelse; Alistair Duff; Michael Farrell; Anil Mehta; Anne Munck; Rodney Pollitt; Isabelle Sermet-Gaudelus; Bridget Wilcken; Manfred Ballmann; Carlo Corbetta; Isabelle de Monestrol; Philip Farrell; Maria Feilcke; Claude Férec; Silvia Gartner; Kevin Gaskin; Jutta Hammermann; Nataliya Kashirskaya; Gerard Loeber; Milan Macek; Gita Mehta; Andreas Reiman; Paolo Rizzotti; Alec Sammon; Dorota Sands; Alan Smyth; Olaf Sommerburg; Toni Torresani; Georges Travert; Annette Vernooij; Stuart Elborn
Journal:  J Cyst Fibros       Date:  2009-02-26       Impact factor: 5.482

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.